Organon & Co. (OGN): Price and Financial Metrics Recent IPO


Organon & Co. (OGN): $29.01

-0.22 (-0.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

OGN Stock Price Chart Interactive Chart >

Price chart for OGN

OGN Price/Volume Stats

Current price $29.01 52-week high $38.75
Prev. close $29.23 52-week low $27.25
Day low $28.91 Volume 1,504,400
Day high $29.40 Avg. volume 3,871,653
50-day MA $31.38 Dividend yield N/A
200-day MA $0.00 Market Cap 7.35B

Organon & Co. (OGN) Company Bio


Organon & Co. Organon & Co. is a science-based global pharmaceutical company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. Its women's health portfolio includes Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. Its operating segments include the Organon Products segment. The Organon Products segment is engaged in developing and delivering health solutions through its portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's products segment portfolio includes: Women's Health, Biosimilars and Established Brands. Women's Health contains contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing and elonva. The Company's Biosimilars portfolio consists of three immunology products: Brenzys, Renflexis and Hadlima; and two oncology products: Ontruzant and Aybintio.


OGN Latest News Stream


Event/Time News Detail
Loading, please wait...

OGN Latest Social Stream


Loading social stream, please wait...

View Full OGN Social Stream

Latest OGN News From Around the Web

Below are the latest news stories about Organon & Co that investors may wish to consider to help them evaluate OGN as an investment opportunity.

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

JERSEY CITY, N.J. & GENEVA, Switzerland, July 27, 2021--Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor

Yahoo | July 27, 2021

Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021

JERSEY CITY, N.J., July 22, 2021--Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021

Yahoo | July 22, 2021

Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?

Neither healthcare stock has performed well so far this year.

The Motley Fool | July 10, 2021

Stay Away From Low-Growth Organon

Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive.

Larry Ramer on InvestorPlace | July 8, 2021

Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

JERSEY CITY, N.J., June 29, 2021--Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

Yahoo | June 29, 2021

Read More 'OGN' Stories Here

OGN Price Returns

1-mo -5.99%
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7743 seconds.